Routine induction therapy in living donor liver transplantation prevents rejection but may promote recurrence of hepatitis C

Transplantation Proceedings

Volumn 44, Issue 5, 2012, Pages 1351-1356

  Ghanekar, A ^a   Kashfi, A ^a   Cattral, M ^a   Selzner, N ^a   McGilvray, I ^a   Selzner, M ^a   Renner, E ^a   Lilly, L ^a   Levy, G ^a   Grant, D ^a   Greig, P ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; BASILIXIMAB; CYCLOSPORIN; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE GRAFT REJECTION; ANTIVIRAL THERAPY; ARTICLE; CANCER RISK; DISEASE SEVERITY; GRAFT SURVIVAL; HEPATITIS C; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RISK; LIVER TRANSPLANTATION; LIVING DONOR; MAJOR CLINICAL STUDY; OPPORTUNISTIC INFECTION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROFESSIONAL STANDARD; RECURRENCE RISK; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL; ANTILYMPHOCYTE SERUM; ANTIVIRAL AGENTS; CHI-SQUARE DISTRIBUTION; FEMALE; GRAFT REJECTION; HEPATITIS C; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; LIVING DONORS; MALE; MIDDLE AGED; ONTARIO; RECOMBINANT FUSION PROTEINS; RECURRENCE; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TRANSPLANTATION CONDITIONING; TREATMENT OUTCOME; VIRUS ACTIVATION;

EID: 84861895810     PISSN: 00411345     EISSN: 18732623     Source Type: Journal    
DOI: 10.1016/j.transproceed.2012.01.117     Document Type: Article

References (36)

1. Ensor CR, Cahoon WD Jr, Hess ML, et al: Induction immunosuppression for orthotopic heart transplantation: a review. Prog Transplant 19:333, 2009
2. Bhorade SM, Stern E: Immunosuppression for lung transplantation. Proc Am Thorac Soc 6:47, 2009
3. Heilman RL, Mazur MJ, Reddy KS: Immunosuppression in simultaneous pancreas-kidney transplantation: progress to date. Drugs 70:793, 2010
4. Padiyar A, Augustine JJ, Hricik DE: Induction antibody therapy in kidney transplantation. Am J Kidney Dis 54:935, 2009
5. Cai J, Terasaki PI: Induction immunosuppression improves long-term graft and patient outcome in organ transplantation: an analysis of United Network for Organ Sharing Registry data. Transplantation 90:1511, 2010
6. Lang KS, Georgiev P, Recher M, et al: Immunoprivileged status of the liver is controlled by Toll-like receptor 3 signaling. J Clin Invest 116:2456, 2006
7. Knechtle SJ, Kwun J: Unique aspects of rejection and tolerance in liver transplantation. Semin Liver Dis 29:91, 2009
8. Liu LU, Bodian CA, Gondolesi GE, et al: Marked differences in acute cellular rejection rates between living-donor and deceased-donor liver transplant recipients. Transplantation 80:1072, 2005
9. Shaked A, Ghobrial RM, Merion RM, et al: Incidence and severity of acute cellular rejection in recipients undergoing adult living donor or deceased donor liver transplantation. Am J Transplant 9:301, 2009
10. Dirsch O, Li J, He Q, et al: Induction of rejection after small-for-size liver transplantation: size matters. J Invest Surg 21:288, 2008
11. Hines IN, Kremer M, Isayama F, et al: Impaired liver regeneration and increased oval cell numbers following T cell-mediated hepatitis. Hepatology 46:229, 2007
12. Soliman T, Hetz H, Burghuber C, et al: Short-term induction therapy with anti-thymocyte globulin and delayed use of calcineurin inhibitors in orthotopic liver transplantation. Liver Transpl 13:1039, 2007
13. Boillot O, Seket B, Dumortier J, et al: Thymoglobulin induction in liver transplant recipients with a tacrolimus, mycophenolate mofetil, and steroid immunosuppressive regimen: a five-year randomized prospective study. Liver Transpl 15:1426, 2009
14. Neuhaus P, Clavien PA, Kittur D, et al: Improved treatment response with basiliximab immunoprophylaxis after liver transplantation: results from a double-blind randomized placebo-controlled trial. Liver Transpl 8:132, 2002
15. Schmeding M, Sauer IM, Kiessling A, et al: Influence of basiliximab induction therapy on long term outcome after liver transplantation, a prospectively randomised trial. Ann Transplant 12:15, 2007
16. Lupo L, Panzera P, Tandoi F, et al: Basiliximab versus steroids in double therapy immunosuppression in liver transplantation: a prospective randomized clinical trial. Transplantation 86:925, 2008
17. Vigano J, Gruttadauria S, Mandala L, et al: The role of basiliximab induction therapy in adult-to-adult living-related transplantation and deceased donor liver transplantation: a comparative retrospective analysis of a single-center series. Transplant Proc 40:1953, 2008
18. Shah SA, Grant DR, Greig PD, et al: Analysis and outcomes of right lobe hepatectomy in 101 consecutive living donors. Am J Transplant 5:2764, 2005
19. Shah SA, Grant DR, McGilvray ID, et al: Biliary strictures in 130 consecutive right lobe living donor liver transplant recipients: results of a western center. Am J Transplant 7:161, 2007
20. DuBay D, Sandroussi C, Sandhu L, et al: Liver transplantation for advanced hepatocellular carcinoma using poor tumor differentiation on biopsy as an exclusion criterion. Ann Surg 253:166, 2011
21. Banff schema for grading liver allograft rejection: an international consensus document. Hepatology 25:658, 1997
22. Bedossa P, Poynard T: An algorithm for the grading of activity in chronic hepatitis C. The METAVTR Cooperative Study Group. Hepatology 24:289, 1996
23. Selzner N, Renner EL, Selzner M, et al: Antiviral treatment of recurrent hepatitis C after liver transplantation: predictors of response and long-term outcome. Transplantation 88:1214, 2009
24. McAlister VC, Haddad E, Renouf E, et al: Cyclosporin versus tacrolimus as primary immunosuppressant after liver transplantation: a meta-analysis. Am J Transplant 6:1578, 2006
25. Greig P, Lilly L, Scudamore C, et al: Early steroid withdrawal after liver transplantation: the Canadian tacrolimus versus microemulsion cyclosporin A trial: 1-year follow-up. Liver Transpl 9:587, 2003
26. Selzner N, Girgrah N, Lilly L, et al: The difference in the fibrosis progression of recurrent hepatitis C after live donor liver transplantation versus deceased donor liver transplantation is attributable to the difference in donor age. Liver Transpl 14:1778, 2008
27. Everson GT: Impact of immunosuppressive therapy on recurrence of hepatitis C. Liver Transpl 8:S19, 2002
28. Selzner N, Grant DR, Shalev I, et al: The immunosuppressive pipeline: meeting unmet needs in liver transplantation. Liver Transpl 16:1359, 2010
29. Belli LS, Burroughs AK, Burra P, et al: Liver transplantation for HCV cirrhosis: improved survival in recent years and increased severity of recurrent disease in female recipients: results of a long term retrospective study. Liver Transpl 13:733, 2007
30. Berenguer M, Prieto M, Cordoba J, et al: Early development of chronic active hepatitis in recurrent hepatitis C virus infection after liver transplantation: association with treatment of rejection. J Hepatol 28:756, 1998
31. Nakagawa M, Sakamoto N, Enomoto N, et al: Specific inhibition of hepatitis C virus replication by cyclosporin A. Biochem Biophys Res Commun 313:42, 2004
32. Berenguer M, Royuela A, Zamora J: Immunosuppression with calcineurin inhibitors with respect to the outcome of HCV recurrence after liver transplantation: results of a meta-analysis. Liver Transpl 13:21, 2007
33. Llado L, Fabregat J, Castellote J, et al: Impact of immunosuppression without steroids on rejection and hepatitis C virus evolution after liver transplantation: results of a prospective randomized study. Liver Transpl 14:1752, 2008
34. Nair S, Loss GE, Cohen AJ, et al: Induction with rabbit antithymocyte globulin versus induction with corticosteroids in liver transplantation: impact on recurrent hepatitis C virus infection. Transplantation 81:620, 2006
35. Thuluvath PJ, Guidinger MK, Fung JJ, et al: Liver transplantation in the United States, 1999-2008. Am J Transplant 10:1003, 2010
36. Martinez OM, de Gruijl FR: Molecular and immunologic mechanisms of cancer pathogenesis in solid organ transplant recipients. Am J Transplant 8:2205, 2008